References The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia

20 June, 2018

References

1.	Chien SC, et al. Antimicrobial Agents Chemother 1997; 41(10): 2256-60.
2.	Chien SC, et al. Antimicrobial Agents Chemother 1998; 42(4): 885-8.
3.	Lynch JP, et al. Drugs In press
4.	Gotfried MHM, et al. Chest 2001; 119: 1114-22.
5.	Lister PD, et al. Diagn Microbiol Infect Dis 2002; 44: 43-9.
6.	Dunbar LM, et al. Clin Infect Dis 2003;37:752-60.
7.	File TM Jr., et al. Current Med Res Opin 2004; 20: 1473-81.
8.	Shorr AF, et al. Clin Ther 2005; 27: 1251-9.
9.	Anzueto A, et al. Clin Infect Dis 2006; 42: 73-81.
10.	Morganroth J, et al. Chest 2005; 128: 3398-406.
11.	Weiss K, et al. Chest 2005; 128: 940-6.
12.	Jumbe N, et al. J Clin Invest 2003;112:275-85.
13.	Smith HJ, et al. Antimicrob Agents Chemother 2004; 48(10): 3954-8.
14.	File TM Jr., et al. Clin Cornerstone 2003;(suppl 3):S21-S8.
15.	Kardas P, et al. J Antimicrob Chemother 2002;49:897-903.
16.	Perez-Gorricho B, et al. Int J Antimicrob Agents 2003;21: 222-8.
17.	Noel GJ, et al. Clin Pharmacol Ther. 2003 ;73(4): 292-303.